Journal of Diagnostics Concepts & Practice ›› 2023, Vol. 22 ›› Issue (01): 37-43.doi: 10.16150/j.1671-2870.2023.01.006
• Original articles • Previous Articles Next Articles
XU Jiankun, ZHOU Luting, ZHANG Wenjing, XU Haimin, WANG Chaofu()
Received:
2022-05-30
Online:
2023-02-25
Published:
2023-07-06
Contact:
WANG Chaofu
E-mail:wangchaofu@126.com
CLC Number:
XU Jiankun, ZHOU Luting, ZHANG Wenjing, XU Haimin, WANG Chaofu. The prognostic value of CA9 expression in clear cell renal cell carcinoma[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01): 37-43.
Figure 1
Representative images of CA9 HE and IHC staining in normal renal epithelial and clear cell renal cell carcinoma ccRCC specimens CA9 was generally negative in normal kidney tissues (a:×10,b:×10,c:×40). CA9 was negatively expressed in clear cell renal cell carcinoma ccRCC (d:×10,e:×10,f:×40). CA9 was expressed in < 85% of clear cell renal cell carcinoma ccRCC tissues (g:×10,h:×10,i:×40). CA9 was expressed in clear cell renal cell carcinoma (ccRCC) ≥85% (j:×10,k:×10,l:×40).
Table 1
Clinicopathological characteristics of patients diagnosed with ccRCC (N=231)
Parameter | Number | Percentage(%) |
---|---|---|
Age (years) | ||
Median | 58 | |
Range | 20~91 | |
Gender | ||
Male | 152 | 65.8 |
Female | 79 | 34.2 |
Tumour site | ||
Left | 118 | 51.1 |
Right | 113 | 48.9 |
Furman grade | ||
1 | 8 | 3.5 |
2 | 148 | 64.0 |
3 | 42 | 18.2 |
4 | 33 | 14.3 |
T stage | ||
Ⅰ | 168 | 72.7 |
Ⅱ | 22 | 9.5 |
Ⅲ | 22 | 9.5 |
Ⅳ | 19 | 8.3 |
Rhabdoid or sarcomatoid differentiation | ||
No | 206 | 89.2 |
Yes | 25 | 10.8 |
Necrosis | ||
No | 182 | 78.8 |
Yes | 49 | 21.2 |
Capsular invasion | ||
No | 206 | 89.2 |
Yes | 25 | 10.5 |
Vascular invasion | ||
No | 211 | 91.3 |
Yes | 20 | 8.7 |
Table 2
The expression of CA9 in ccRCC and the single factor Chi-square analysis of clinicopathologic features
Parameter | Amount | CA9 expression | P | |
---|---|---|---|---|
Negative | Positive | |||
Age (years) | ||||
≤55 | 84 | 26(31.0%) | 58(69.0%) | 0.494 |
>55 | 147 | 52(35.4%) | 95(64.6%) | |
Gender | ||||
Male | 152 | 58(38.2%) | 94(61.8%) | 0.050 |
Female | 79 | 20(25.3%) | 59(74.7%) | |
Tumour site | ||||
Left | 118 | 38(32.2%) | 80(67.8%) | 0.608 |
Right | 113 | 40(35.4%) | 73(64.6%) | |
Furman grade | ||||
1-2 | 156 | 38(24.4%) | 118(75.6%) | <0.001 |
3-4 | 75 | 40(53.3%) | 35(46.7%) | |
T stage | ||||
Ⅰ-Ⅱ | 190 | 44(23.2%) | 146(76.8%) | <0.001 |
Ⅲ-Ⅳ | 41 | 34(82.9%) | 7(17.1%) | |
Rhabdoid or sarcomatoid differentiation | ||||
No | 206 | 58(28.2%) | 148(71.8%) | <0.001 |
Yes | 25 | 20(80.0%) | 5(20.0%) | |
Necrosis | ||||
No | 182 | 42(23.1%) | 142(76.9%) | <0.001 |
Yes | 49 | 36(73.5%) | 13(26.5%) | |
Capsular invasion | ||||
No | 206 | 59(28.6%) | 147(71.4%) | <0.001 |
Yes | 25 | 19(76.0%) | 6(24.0%) | |
Vascular invasion | ||||
No | 211 | 61(28.9%) | 150(71.1%) | <0.001 |
Yes | 20 | 17(85.0%) | 3(15.0%) | |
Relapse or metastasis | ||||
No | 193 | 45(23.3%) | 148(76.7%) | <0.001 |
Yes | 38 | 33(86.8%) | 5(13.2%) |
Table 3
Univariate and multivariate analysis of OS in ccRCC patients
Parameter | Univariate analysis | multivariate analysis | |
---|---|---|---|
P | Risk ratio(95%CI) | P | |
Gender | <0.001 | 0.102(0.013-0.767) | 0.027 |
Tumour site | 0.235 | ||
Age(>55 years) | 0.840 | ||
Furman Grade(3-4) | <0.001 | 0.534(0.165-1.724) | 0.294 |
Rhabdoid differentiation | <0.001 | 1.106(0.375-3.261) | 0.855 |
Necrosis | <0.001 | 0.725(0.210-2.500) | 0.610 |
T Stage(Ⅲ-Ⅳ) | <0.001 | 1.131(0.223-5.730) | 0.882 |
Capsular invasion | <0.001 | 0.503(0.130-1.944) | 0.319 |
Vascular invasion | <0.001 | 0.491(0.141-1.710) | 0.264 |
CA9 low expression | <0.001 | 6.211(1.908-20.00) | 0.002 |
Table 4
Univariate and multivariate analysis of DFS in ccRCC
Parameter | Univariate analysis | Multivariate analysis | |
---|---|---|---|
P | Risk ratio(95%CI) | P | |
Gender | 0.001 | 0.356(0.123-1.025) | 0.056 |
Tumour site | 0.483 | ||
Age(>55 years) | 0.295 | ||
Furman Grade(3-4) | <0.001 | 0.404(0.159-1.026) | 0.057 |
Rhabdoid differentiation | <0.001 | 1.040(0.458-2.359) | 0.926 |
Necrosis | <0.001 | 0.746(0.290-1.920) | 0.543 |
T Stage(Ⅲ-Ⅳ) | <0.001 | 1.591(0.460-5.511) | 0.464 |
Capsular invasion | <0.001 | 0.350(0.121-1.011) | 0.052 |
Vascular invasion | <0.001 | 0.616(0.229-1.658) | 0.337 |
CA9 low expression | <0.001 | 8.980(3.219~25.057) | <0.001 |
[1] |
HSIEH J J, PURDUE M P, SIGNORETTI S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3:17009.
doi: 10.1038/nrdp.2017.9 pmid: 28276433 |
[2] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34.
doi: 10.3322/caac.v69.1 URL |
[3] |
GRAY R E, HARRIS G T. Renal Cell Carcinoma: Diagnosis and Management[J]. Am Fam Physician, 2019, 99(3):179-184.
pmid: 30702258 |
[4] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
doi: 10.3322/caac.v68.6 URL |
[5] |
COHEN H T, MCGOVERN F J. Renal-cell carcinoma[J]. N Engl J Med, 2005, 353(23):2477-2490.
doi: 10.1056/NEJMra043172 URL |
[6] |
KROEGER N, ZIMMERMANN U, BURCHARDT M, et al. Prognostication in localised renal cell carcinoma[J]. Lancet Oncol, 2015, 16(6):603-604.
doi: 10.1016/S1470-2045(15)70227-5 pmid: 25979596 |
[7] |
LEIBOVICH B C, HAN K R, BUI M H, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials[J]. Cancer, 2003, 98(12):2566-2575.
pmid: 14669275 |
[8] |
KLATTE T, ROSSI S H, STEWART G D. Prognostic factors and prognostic models for renal cell carcinoma: a lite-rature review[J]. World J Urol, 2018, 36(12):1943-1952.
doi: 10.1007/s00345-018-2309-4 |
[9] |
RENSHAW A A, CHEVILLE J C. Quantitative tumour necrosis is an independent predictor of overall survival in clear cell renal cell carcinoma[J]. Pathology, 2015, 47(1):34-37.
doi: 10.1097/PAT.0000000000000193 URL |
[10] |
TSUI K H, SHVARTS O, SMITH R B, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria[J]. J Urol, 2000, 163(4):1090-1095.
doi: 10.1016/s0022-5347(05)67699-9 pmid: 10737472 |
[11] |
LAM J S, LEPPERT J T, FIGLIN R A, et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma[J]. Urology, 2005, 66(5 Suppl):1-9.
doi: 10.1016/j.urology.2005.06.112 pmid: 16194700 |
[12] |
BUI M H, ZISMAN A, PANTUCK A J, et al. Prognostic factors and molecular markers for renal cell carcinoma[J]. Expert Rev Anticancer Ther, 2001, 1(4):565-575.
doi: 10.1586/14737140.1.4.565 URL |
[13] |
KIM H L, SELIGSON D, LIU X, et al. Using tumor mar-kers to predict the survival of patients with metastatic renal cell carcinoma[J]. J Urol, 2005, 173(5):1496-1501.
doi: 10.1097/01.ju.0000154351.37249.f0 URL |
[14] |
IVANOV S, LIAO S Y, IVANOVA A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer[J]. Am J Pathol, 2001, 158(3):905-919.
pmid: 11238039 |
[15] |
MAXWELL P H, WIESENER M S, CHANG G W, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis[J]. Nature, 1999, 399(6733):271-275.
doi: 10.1038/20459 URL |
[16] | BUI M H, SELIGSON D, HAN K R, et al. Carbonic anhydrase Ⅸ is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy[J]. Clin Cancer Res, 2003, 9(2):802-811. |
[17] | BENEJ M, PASTOREKOVA S, PASTOREK J. Carbonic anhydrase Ⅸ: regulation and role in cancer[J]. Subcell Biochem, 2014, 75:199-219. |
[18] | TAFRESHI N K, LLOYD M C, BUI M M, et al. Carbonic anhydrase Ⅸ as an imaging and therapeutic target for tumors and metastases[J]. Subcell Biochem, 2014, 75:221-254. |
[19] |
ZATOVICOVA M, JELENSKA L, HULIKOVA A, et al. Carbonic anhydrase Ⅸ as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain[J]. Curr Pharm Des, 2010, 16(29):3255-3263.
doi: 10.2174/138161210793429832 URL |
[20] |
ZHAO Z, LIAO G, LI Y, et al. Prognostic value of carbonic anhydrase Ⅸ immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature[J]. PLoS One, 2014, 9(11):e114096.
doi: 10.1371/journal.pone.0114096 URL |
[21] |
LEIBOVICH B C, SHEININ Y, LOHSE C M, et al. Carbonic anhydrase Ⅸ is not an independent predictor of outcome for patients with clear cell renal cell carcinoma[J]. J Clin Oncol, 2007, 25(30):4757-4764.
doi: 10.1200/JCO.2007.12.1087 URL |
[22] |
SANDLUND J, OOSTERWIJK E, GRANKVIST K, et al. Prognostic impact of carbonic anhydrase Ⅸ expression in human renal cell carcinoma[J]. BJU Int, 2007, 100(3):556-560.
doi: 10.1111/bju.2007.100.issue-3 URL |
[23] |
PATARD J J, FERGELOT P, KARAKIEWICZ P I, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma[J]. Int J Cancer, 2008, 123(2):395-400.
doi: 10.1002/ijc.23496 URL |
[24] |
SOYUPAK B, ERDOĞAN S, ERGIN M, et al. CA9 expression as a prognostic factor in renal clear cell carcinoma[J]. Urol Int, 2005, 74(1):68-73.
pmid: 15711113 |
[25] |
LAGUNA M P. Re: carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up[J]. J Urol, 2014, 191(1):54-55.
doi: 10.1016/j.juro.2013.09.047 pmid: 24331469 |
[26] |
ZERATI M, LEITE K R, PONTES-JUNIOR J, et al. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma-a digital analysis of tissue microarray[J]. Int Braz J Urol, 2013, 39(4):484-492.
doi: 10.1590/S1677-5538.IBJU.2013.04.05 URL |
[1] | WANG Zhaohui, WU Haibo. Clinicopathological analysis of 31 cases of gastric schwannoma [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 552-556. |
[2] | LI Juan, LIU Jingsong, LI Mei, LI Dianwei, ZHU Hong. Bronchiolar adenoma: a clinic pathological analysis of 10 cases and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(05): 466-470. |
[3] | WEI Ruoqu, YU Hong, YAO Zhirong. Fibroblastic connective tissue nevus in children: a case report and literature review [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(02): 190-194. |
[4] | XU Zhaoping, WANG Haofei. Expression of ZNF692 gene in clear cell renal cell carcinoma and its relationship with prognosis [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 292-296. |
[5] | MENG Leijun, ZHANG Jing, WANG Xueli, LI Zhi, ZHANG Hong, ZENG Naiyan. Identification of differentially expressed target genes in pediatric Burkitt lymphoma and its clinical application [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 248-257. |
[6] | JIN Jiaoying, LI Qianyu, JIANG Hongwei, HAN Dongyan, XI Hao, WEI Qing. Report of a case of composite pheochromocytoma and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(2): 165-169. |
[7] | HE Yanyan, FENG Lijin, WEI Qing. Pleomorphic giant cell adenocarcinoma of prostate: clinicopathological analysis of a case and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(2): 160-164. |
[8] | WANG Shunli, DENG Shuangshuang, GAO Hui, XIAO Tianyu, GAO Jinli. Analysis of clinicopathological characteristics of breast encapsulated papillarycarcinoma [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 89-92. |
[9] | HAN Dongyan, FU Huijun, HE Yanyan, XI Hao, WEI Qing. Endolymphatic sac tumor: Clinicopathological features and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(06): 711-714. |
[10] | ZHU Peipei, ZOU Jue, CHEN Jun, XU Rongrong, YAN Hongzhu. Intracranial solitary fibrous tumor/hemangiopericytoma: a clinicopathologic study of 20 cases with review of literature [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(06): 622-626. |
[11] | YI Lin, XIAO Li, CHEN Yan, YIN Yulei. Anaplastic large cell lymphoma: a clinicopathological study and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(03): 313-319. |
[12] | HAN Dongyan, LI Qianyu, JIANG Hongwei, XI Hao, WEI Qing. Clinicopathological features of primary renal angiosarcoma: report of 3 cases and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(02): 183-187. |
[13] | QIAO Changting, LI Lei, WU Anni, YUAN Fei. Relationship between HER2 expression and clinicopathological features in advanced gastric cancer [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(02): 166-170. |
[14] | JIN Jingjing, XIAO Li, GU Yan, YIN Yulei. Comparison of immunohistochemistry and immunofluorescence in renal core biopsy specimen [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 79-83. |
[15] | SHI Ke, LÜ Xinquan. The use of p16/Ki-67 double-staining in diagnosis of cervical intraepithelial lesion [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 602-607. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||